![Separations | Free Full-Text | Improved Achiral and Chiral HPLC-UV Analysis of Ruxolitinib in Two Different Drug Formulations Separations | Free Full-Text | Improved Achiral and Chiral HPLC-UV Analysis of Ruxolitinib in Two Different Drug Formulations](https://pub.mdpi-res.com/separations/separations-07-00047/article_deploy/html/images/separations-07-00047-g003.png?1599470809)
Separations | Free Full-Text | Improved Achiral and Chiral HPLC-UV Analysis of Ruxolitinib in Two Different Drug Formulations
![CAS 1092939-17-7 Ruxolitinib Phosphate Raw Material Powder - China Ruxolitinib Phosphate, Ruxolitinib Phosphate Powder | Made-in-China.com CAS 1092939-17-7 Ruxolitinib Phosphate Raw Material Powder - China Ruxolitinib Phosphate, Ruxolitinib Phosphate Powder | Made-in-China.com](https://image.made-in-china.com/2f0j00dLyoBaJPSDkM/CAS-1092939-17-7-Ruxolitinib-Phosphate-Raw-Material-Powder.webp)
CAS 1092939-17-7 Ruxolitinib Phosphate Raw Material Powder - China Ruxolitinib Phosphate, Ruxolitinib Phosphate Powder | Made-in-China.com
![These highlights do not include all the information needed to use JAKAFI safely and effectively. See full prescribing information for JAKAFI. JAKAFI® (ruxolitinib) tablets, for oral use Initial U.S. Approval: 2011 These highlights do not include all the information needed to use JAKAFI safely and effectively. See full prescribing information for JAKAFI. JAKAFI® (ruxolitinib) tablets, for oral use Initial U.S. Approval: 2011](https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=jakafi-9.jpg&id=693980)